Can a new governor, an oligarch from the region, restore calm in the face of a depressed economy, corruption, and a pro-Russian political establishment?
Lamborghini, Ferrari, Maserati, McLaren, and Porsche are all popular among the filthy rich
The U.S. provides hope that much of the world could eventually avoid both malnutrition and excess nutrition
Microsoft's Xbox One sales need a big boost from exclusive game Titanfall
Comcast might please shareholders by spinning off some 3 million subscribers. How long could the new cable company survive independently?
Groups representing professional photographers prefer to develop ways to pay image creators in place of Getty's tolerance for Web embedding
DIsney's MyMagic+ technology may make a trip to Disney World more magical—or creep customers out
European MBA programs compete with top-tier U.S. schools for the best students at home and abroad
Research suggests that women may turn to entrepreneurship after 50 to support themselves in retirement
Founder: Dr. John Hadden
VC Investment over the last four quarters: $25 million
IRX Therapeutics is a 40-employee biotech firm developing drugs to restore immune system function, particularly in patients with head and neck cancer. Founded over a decade ago and backed by more than $60 million raised mostly from high-net-worth individuals, the company has reduced headcount by a third and delayed some clinical trials planned for 2009, according to Chief Financial Officer Jeffrey Hwang.
Key to startup success: "In normal times where the capital is available, the difference maker among people with good ideas is sharp execution. There's never a substitute for the ability to attract and retain experienced, qualified people to take advantage of the discovery you've made."